Skip to main content

TriLink Receives $100,000 SBIR Grant

By a GenomeWeb Staff Reporter

NEW YORK (GenomeWeb News) – TriLink BioTechnology said today it has received a $100,000 Phase I Small Business Innovation Research grant from the National Institutes of Health to develop a Hot Start approach for Ligase Chain Reaction.

With the grant, which lasts until July, the San Diego company will use chemically modified ligation components containing thermolabile protecting groups to eliminate problems often seen in LCR, including specificity issues and false-positive signals. The company hopes its approach will eventually lead to LCR replacing applications where traditional PCR, Gap-LCR, and PCR/ ligation combination approaches are too expensive, not applicable, or problematic, it said.

The grant is the fifth the company has received and follows a Phase II SBIR grant of $725,000 in June to continuing study DNA ligase.

The Scan

WHO OKs Emergency Use of Sinopharm Vaccine

The World Health Organization has granted emergency approval for Sinopharm's SARS-CoV-2 vaccine, the Guardian reports.

Scientific Integrity Panel to Meet

According to the Associated Press, a new US scientific integrity panel is to meet later this week.

Trying in the Eye

NPR reports that a study of Editas Medicine's CRISPR therapy for Leber congenital amaurosis has begun.

PLOS Papers on Cerebellum Epigenetics, Copy Number Signature Tool, Acute Lung Injury Networks

In PLOS this week: epigenetics analysis of brain tissue, bioinformatics tool to find copy number signatures in cancer, and more.